drugset / Trial / NCT04540705
A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is in Part 1, to determine the safety of nivolumab, bempegaldesleukin (BEMPEG: NKTR-214), and Tyrosine Kinase Inhibitor (TKI) combination.
Timeline
- Start
- 2020-09-11
- Primary completion
- 2024-01-18
- Completion
- 2024-01-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Axitinib | Small molecule | — | — |
| Subject | Cabozantinib | Small molecule | — | — |
| Subject | Nivolumab | Monoclonal antibody | — | — |